Patents Assigned to MARVEL BIOTECHNOLOGY
  • Purine compounds for treating disorders
    Patent number: 12570656
    Abstract: Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: March 10, 2026
    Assignee: MARVEL BIOTECHNOLOGY
    Inventor: Mark Williams
  • PURINE COMPOUNDS FOR TREATING DISORDERS
    Publication number: 20250353849
    Abstract: Purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for treating cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinson's. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught. Form. (I) & (II).
    Type: Application
    Filed: December 2, 2022
    Publication date: November 20, 2025
    Applicant: MARVEL BIOTECHNOLOGY
    Inventor: Mark WILLIAMS
  • NOVEL ANTI-DEPRESSANT AND NEUROPLASTIC AGENTS AND THERAPEUTIC USES THEREOF
    Publication number: 20250002512
    Abstract: A compound of Formula (6): Formula (8): and Formula (10): are prepared and found useful in the treatment and/or prevention of diseases and conditions such as Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, fetal alcohol exposure, autism, schizophrenia, traumatic brain injury, stroke, addictions, Huntington's disease, Fragile X and Rett's syndrome.
    Type: Application
    Filed: October 26, 2022
    Publication date: January 2, 2025
    Applicant: MARVEL BIOTECHNOLOGY
    Inventor: Mark WILLIAMS